期刊文献+

复发性外阴阴道假丝酵母菌病治疗的临床分析 被引量:2

Clinical Analysis on the Treatment of Relapsed Vulvovaginal Candida Mycoderma Bacteria
下载PDF
导出
摘要 目的:探讨在复发性外阴阴道假丝酵母菌病中使用微生态制剂的治疗效果。方法:将复发性念珠菌性外阴阴道炎320例随机分为对照组(单独抗真菌治疗)与治疗组(抗真菌治疗联合微生态制剂)。治疗前、后1周,1个月、3个月、6个月月经干净后进行临床、真菌学疗效分析。结果:经抗真菌治疗后,临床、真菌学疗效较好。治疗后1个月,治疗组有效率明显高于对照组(P <0.01),治疗后3个月、6个月、12月复发率均低于对照组(P<0.01或<0.05)。结论:抗真菌药物联合微生态制剂治疗复发性外阴阴道假丝酵母菌病效果好,复发率低。 Objective: To discuss the effect of microbial ecological agents for the treatment of relapsed vulvovaginal candida myco- derma bacteria. Method: 320 cases with relapsed vulvovaginal candida mycoderma bacteria were randomly divided into control group (antifungal therapy) and treatment group (antifungal therapy combined with microbial ecological agents). The clinical and mycology effect before and after treatment for lw as well as in lm, 3m, 6m were analyzed. Result: Patients have good clinical and mycology effect after antifungal therapy. Treatment group's effective rate is obviously higher than control group in lm (P〈0. 01), and its recurrence rate is lower than control group in 3m, 6m and 12m (P〈0.01 or P〈0.05). Conclusion: The treatment of relapsed vulvovaginal candida mycoderma bacteria by the combination of antifungal therapy and microbial ecological agents has good effect with low recurrence rate.
作者 蒙俊
出处 《内蒙古中医药》 2010年第1期18-20,共3页 Inner Mongolia Journal of Traditional Chinese Medicine
关键词 假丝酵母菌病 外阴阴道 微生态制剂 氟康唑 Candida mycodcrma bacteria Vulvovaginal Microbial ecological agents Fluconazole
  • 相关文献

参考文献2

二级参考文献26

  • 1Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis : epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol,1998, 178:203.
  • 2Sobel JD, Kapemick PS, Zervos M et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole.Am J Obstet Gynecol, 2001, 185 : 363.
  • 3Sobel JD. Pathogenesis of recurrent vulvovaginal candidiasis. Curr Inibet Dis Rap, 2002, 4:514.
  • 4Fidel PL Jr, Lynch ME, Sobel JD. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis.Infect Immun, 1993,61 (5): 1990 - 1995.
  • 5Fidel PL Jr, Lynch ME, Sobel JD. Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun, 1994,62 (3): 1032 - 1038.
  • 6Fidel PL Jr, Lynch ME, Sobel JD. Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect Immun, 1995,63 (7) :2403 - 2408.
  • 7Cantoma M, Mook D, Balish E. Resistance of congenitally immunodeficient gnotobiotic mice to vaginal candidiasis. Infect Immun, 1990,58(11) :3813 -3815.
  • 8Fidel PL Jr, Lynch ME, Conaway DH, et al. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun, 1995, 63(2) :547 -553.
  • 9Taylor BN, Saavedra M, Fidel PL Jr. Local Thl/Th2 cytokine production during experimental vaginal candidiasis: potential importance of transforming growth factor-beta. Med Mycol, 2000, 38 (6):419 -431.
  • 10Saavedra M, Taylor B, Lukacs N, et al. Local production of chemokines during experimental vaginal candidiasis. Infect Immun, 1999,67(11):5820-5826.

共引文献19

同被引文献35

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部